Aktien in diesem Artikel
indizes in diesem Artikel
13 patents pending in the US and Canada Signed supply agreement with
FSD Pharma Inc and World Class Extractions Inc to purchase hemp flower from supplier Thomas Elcome Teamed up with a leading orthopedic surgeon at the University of British Columbia for a cannabis tablet trial Canntab is in the process of building its manufacturing facility within the FSD Pharma plant What Canntab Therapeutics
does Canntab Therapeutics Ltd (CSE:PILL) (OTCMKTS: CTABF) is dedicated to the research and development of oral dosage therapeutic formulations of cannabis. The Ontario-based company has 13 patents pending in the US and Canada. Canntab's oral delivery system treats different ailments by delivering a uniform dosage of medicinal cannabis extract. This includes extended-release, flash melt, immediate release, modified release and bi-layered tablets. The company is the first to offer medical cannabis in pill form and its suite of products continues to grow. Canntab's goal is to become a global leader of research in, production of, and education about hard pill oral dosage therapeutic cannabis. The tablets are intended to treat a variety of disorders including Post-Traumatic Stress Disorder and arthritis and can also act as a pain management and appetite loss drug for patients undergoing cancer treatments. Canntab has also entered into a supply agreement with FSD Pharma and World Class Extractions to purchase hemp flower, which will be processed into gel capsules and tablets. How is it doing? The company has had a busy few months, with exciting things to come. Canntab recently signed a supply and loan agreement with FSD Pharma Inc, the licensed Canadian cannabis producer (CSE:HUGE), and extraction company World Class Extractions, to purchase hemp flower from Thomas Elcome. The trio will buy up to C$5 million of Thomas Elcome’s hemp crop for five years starting in 2019 at C$100 per kg per 1% of cannabidiol (CBD) extracted from the flower. The three companies earlier struck a deal to buy about 1,000 kg of Thomas Elcome’s 2018 hemp crop. The trio will process Elcome’s organic hemp flower crop into gel capsules and tablets at FSD’s facility in Cobourg, Ontario, which is currently being transformed into a large hydroponic indoor cannabis production and processing facility. “This latest supply agreement will provide us with a significant amount of CBD oil over the next five years, which is required to manufacture our extensive suite of products for sale upon approval by Health Canada,” said Canntab Therapeutics CEO Jeffrey Renwick in a statement. Canntab is in the process of building its own manufacturing facility, within the FSD Pharma plant, to produce cannabis oral dose delivery platforms. In the meantime, the company has converted another room (formerly known as grow room No. 6) into its interim facilities located within FSD’s Health Canada-approved facility, which through its wholly owned subsidiary FV Pharma Inc, has been issued a standard processing licence from Health Canada. In other exciting news, the company has teamed up with a leading orthopedic surgeon at the University of British Columbia for a cannabis tablet trial aimed at reducing the need for opioids. Canntab plans to create the tablets for the study with FSD Pharma. Led by Dr. Don Garbuz, the randomized, double-blind, placebo-controlled clinical trial will test the effectiveness of the Canntab’s product in reducing the need for opioids after knee-replacement surgery. Needless to say, the uses could stretch much further than this, if successful. The University ethics approvals process is underway, with a decision expected shortly. CFO says capsules will likely come first “Right now, we’re just waiting to get the final go-ahead from Health Canada… We’d like to think that we could be in the market commercially, selling capsules at a minimum, by mid-year 2019,” says Canntab CFO, Richard Goldstein Contact Katie Lewis at email@example.comWeiter zum vollständigen Artikel bei "Proactiveinvestors"